FOR IMMEDIATE RELEASE
- Sponsorship connects Cellgenic’s Argentina commercial operations to Latin America’s leading facial-rejuvenation and aesthetic-medicine congress
- Master Hub LatAm 2026 runs October 15–16 at the Hilton Buenos Aires, led by scientific director Dr. Fernando Felice
- Event draws 12+ international speakers across regenerative therapies, injectables, and longevity tracks
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Master Hub LatAm 2026, described by organizers as the most important aesthetic medicine and facial rejuvenation congress in Latin America.
Master Hub LatAm 2026 takes place October 15–16 at the Hilton Hotel in Buenos Aires, Argentina, under scientific director and founder Dr. Fernando Felice, a plastic surgeon and professor at Universidad de Buenos Aires. The 2026 program features more than 12 international speakers across sessions on regenerative therapies, advanced technologies, neuromodulators, and longevity medicine.
The sponsorship builds on Cellgenic’s July 2026 launch of regulated commercial operations in Argentina, extending the Company’s regional presence into one of the country’s highest-visibility medical-aesthetics events and giving Cellgenic direct access to the congress’s international physician and injector audience.
“Master Hub LatAm is where the region’s leading aesthetic physicians go to see what’s next,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Sponsoring this year’s congress puts Cellgenic’s regenerative technologies directly in front of that audience, right as we’re scaling our commercial operations across Argentina.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com
